Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
ADGRB3 Biologics Sequence Review Report 2026: Adhesion G protein-coupled receptor B3 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of ADGRB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
PTPRZ1 Biologics Sequence Review Report 2026: Receptor-type tyrosine-protein phosphatase zeta Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of PTPRZ1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TGFA Biologics Sequence Review Report 2026: Protransforming growth factor alpha Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TGFA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
TFRC Biologics Sequence Review Report 2026: Transferrin receptor protein 1 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of TFRC protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CR2 Biologics Sequence Review Report 2026: Complement receptor type 2 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LY86 Biologics Sequence Review Report 2026: Lymphocyte antigen 86 Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of LY86 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
LIFR Biologics Sequence Review Report 2026: Leukemia inhibitory factor receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of LIFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CNTFR Biologics Sequence Review Report 2026: Ciliary neurotrophic factor receptor subunit alpha Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of CNTFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
FOLR2 Biologics Sequence Review Report 2026: Folate receptor beta Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of FOLR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EPOR Biologics Sequence Review Report 2026: Erythropoietin receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of EPOR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
ESR1 Biologics Sequence Review Report 2026: Estrogen receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of ESR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
EGFR Biologics Sequence Review Report 2026: Epidermal growth factor receptor Similarity and Patent-Risk Signals
18 August 2026
A Biology Modality MCP review of EGFR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
<<
250
251
252
253
254
>>
1905
>